aaic-2026-novel-therapeutic-targets

AAIC 2026: Novel Therapeutic Targets and Disease-Modifying Approaches

Conference: Alzheimer's Association International Conference (AAIC) 2026 Dates: July 12-15, 2026 Location: ExCeL London, UK Theme: Building Bridges in Alzheimer's Research

Executive Summary

AAIC 2026 showcases a maturing therapeutic pipeline for Alzheimer's disease and related dementias. Beyond the anti-amyloid antibodies (lecanemab, donanemab) that have received regulatory approval, the conference highlights multiple novel therapeutic targets and disease-modifying approaches representing the next generation of treatments[@Cummings2024].

Novel Molecular Targets

1. TREM2 Agonists — Microglial Modulation

The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most promising emerging targets. TREM2 variants significantly influence Alzheimer's disease risk, and therapeutic agonism may restore beneficial microglial functions.

Mechanism: TREM2 signaling promotes microglial survival, proliferation, and phagocytosis of amyloid plaques. Loss-of-function variants impair these protective responses.

Related Mechanisms:

• [TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
• [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
• [Microglial Dysfunction in AD](/mechanisms/trem2-microglial-dysfunction-ad-causal-chain)
• [TREM2-APOE Axis](/mechanisms/trem2-apoe-axis)

AAIC 2026: Novel Therapeutic Targets and Disease-Modifying Approaches

Conference: Alzheimer's Association International Conference (AAIC) 2026 Dates: July 12-15, 2026 Location: ExCeL London, UK Theme: Building Bridges in Alzheimer's Research

Executive Summary

AAIC 2026 showcases a maturing therapeutic pipeline for Alzheimer's disease and related dementias. Beyond the anti-amyloid antibodies (lecanemab, donanemab) that have received regulatory approval, the conference highlights multiple novel therapeutic targets and disease-modifying approaches representing the next generation of treatments[@Cummings2024].

Novel Molecular Targets

1. TREM2 Agonists — Microglial Modulation

The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most promising emerging targets. TREM2 variants significantly influence Alzheimer's disease risk, and therapeutic agonism may restore beneficial microglial functions.

Mechanism: TREM2 signaling promotes microglial survival, proliferation, and phagocytosis of amyloid plaques. Loss-of-function variants impair these protective responses.

Related Mechanisms:

• [TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
• [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
• [Microglial Dysfunction in AD](/mechanisms/trem2-microglial-dysfunction-ad-causal-chain)
• [TREM2-APOE Axis](/mechanisms/trem2-apoe-axis)

2. Synaptic Function Preservation

Synaptic loss correlates most strongly with cognitive decline, making synaptic protection a critical therapeutic goal.

Key Targets:

• PSD-95 stabilization
• NMDA receptor modulation
• AMPA receptor positive allosteric modulators
• Synaptic vesicle protein regulators

• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
• [Synaptic Loss in AD](/mechanisms/synaptic-loss-ad-pathway)
• [Long-Term Potentiation](/mechanisms/long-term-potentiation)
• [Synaptic Vesicle Cycling](/mechanisms/synaptic-vesicle-cycling-neurodegeneration)

3. Neuroinflammation Modulation

The neuroinflammatory cascade involves multiple signaling pathways that can be targeted therapeutically.

Targeted Pathways:

• IL-1β neutralizing antibodies
• TNF-α inhibition
• IL-6 receptor blockade
• NLRP3 inflammasome inhibitors

• [Neuroinflammation in AD](/mechanisms/neuroinflammation)
• [NLRP3 Inflammasome Pathway](/mechanisms/nlrp3-inflammasome-pathway)
• [Complement System Pathway](/mechanisms/complement-system-pathway)
• [NF-κB Signaling in Neurodegeneration](/mechanisms/nfkb-signaling-neurodegeneration)

4. Metabolic and Mitochondrial Targets

Cerebral hypometabolism is an early feature of Alzheimer's disease. Restoring brain energy homeostasis represents a novel therapeutic approach.

Key Targets:

• NAD+ precursors (nicotinamide riboside, NMN)
• Mitophagy enhancers
• Mitochondrial biogenesis stimulators

• [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Mitochondrial Dynamics Pathway](/mechanisms/mitochondrial-dynamics-pathway)
• [Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Sirtuin Signaling in Neurodegeneration](/mechanisms/sirtuin-signaling-neurodegeneration)

5. Tau-Targeted Approaches

With anti-amyloid therapies now approved, tau has emerged as the next major target for disease modification.

Approaches:

• Anti-tau antibodies (various epitopes)
• Tau acetylation inhibitors (HDAC6 modulators)
• Tau aggregation breakers
• Oligomer-specific antibodies

• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Tau Seeding and Propagation](/mechanisms/tau-seeding-propagation)
• [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-tau-proteostasis)

6. Gene Therapy Approaches

Gene therapy for neurodegenerative diseases has matured significantly, with multiple programs advancing to clinical stages.

Delivery Systems:

• AAV vectors with enhanced CNS tropism
• Novel capsids for improved brain targeting

Related Mechanisms:

• [AAV Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)
• [CRISPR Gene Editing](/therapeutics/crispr-cas9-gene-therapy-neurodegeneration)
• [Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy-neurodegeneration)

Disease-Modifying Strategies

Combination Therapy Approaches

AAIC 2026 highlights the shift toward combination therapies targeting multiple pathological hallmarks:

Related Mechanisms:

• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Convergent Pathways in Neurodegeneration](/mechanisms/convergent-pathways-neurodegeneration)

Biomarker-Guided Patient Selection

• Plasma biomarkers (p-tau217, p-tau181, GFAP)
• Tau PET for patient stratification
• Genetic stratification (APOE, polygenic risk scores)

• [p-tau217 Biomarker](/biomarkers/p-tau-217)
• [Integrated Biomarker Panel](/biomarkers/combination-biomarker-panels-ad)

Precision Medicine Approaches

• Autosomal dominant AD: DIAN-TU trial updates
• Down syndrome: Alzheimer's prevention in trisomy 21
• Early-onset AD: Targeted therapeutic approaches

• [Down Syndrome Neurodegeneration](/mechanisms/down-syndrome-neurodegeneration)
• [Sporadic AD Pathway](/mechanisms/sporadic-alzheimers-pathway)

Repurposed Drug Programs

AAIC 2026 features updates on drug repurposing candidates:

| Drug | Original Indication | AD Target | Stage |
|------|---------------------|-----------|-------|
| Metformin | Diabetes | Insulin sensitization | Phase 3 |
| GLP-1 agonists | Diabetes | Neuroprotection | Phase 2/3 |
| SGLT2 inhibitors | Diabetes | Metabolic benefits | Phase 2 |
| Valacyclovir | Herpes | Antiviral approach | Phase 2 |

Related Mechanisms:

• [Type 3 Diabetes Hypothesis](/mechanisms/type-3-diabetes)
• [Insulin Resistance in AD](/mechanisms/insulin-resistance-ad)

Therapeutic Pipeline Overview

Related AAIC 2026 Content

• [AAIC 2026 Conference Main Page](/events/aaic-2026)
• [AAIC 2026: Therapeutic Approaches](/events/aaic-2026/therapeutic-approaches)
• [AAIC 2026: Clinical Trials Update](/events/aaic-2026/clinical-trials-update)
• [AAIC 2026: Gene Therapy Developments](/events/aaic-2026/gene-therapy-developments)
• [AAIC 2026: Neuroinflammation Session](/events/aaic-2026/neuroinflammation)

Key Takeaways

References

External Links

• [AAIC 2026](https://aaic.alz.org)
• [Alzheimer's Association](https://www.alz.org)
• [ClinicalTrials.gov - Alzheimer's Disease](https://clinicaltrials.gov/)